Ways to improve endocrine therapy in postmenopausal women with ER+/ HER2- breast cancer
- Authors: Dzhelyalova M.A.1, Semiglazov V.F1
-
Affiliations:
- N. Petrov National Medical Research Center of Oncology
- Issue: Vol 28, No 11 (2021)
- Pages: 66-69
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313278
- DOI: https://doi.org/10.18565/pharmateca.2021.11.66-69
- ID: 313278
Cite item
Open Access
Access granted
Abstract
The activation of cyclin-dependent kinases 4/6 (CDK 4/6) is one of the important factors of resistance to endocrine therapy for breast cancer (BC). The development and use of CDK 4/6 inhibitors, including palbociclib, ribociclib, abemacyclib, improves the effectiveness of endocrine therapy in patients with ER+/HER2- breast cancer. Ribocyclib in combination with fulvestrant has shown significant progression-free survival and overall survival (OS) benefits in patients with hormone receptor positive (HR+) and negative for human epidermal growth factor receptor 2 (HER2-) advanced breast cancer. The MONALEESA-3 study presents new data on the patients’ survival in a phase III clinical trial of CDK 4/6 inhibitors in patients with advanced breast cancer (median 56.3 months). In this study, data were obtained confirming the increase in OS with longer follow-up. Median OS was 12 months higher in patients with HR+/HER2- advanced breast cancer who received ribociclib in combination with fulvestrant compared with fulvestrant alone. Also, in order to improve treatment results, attempts to determine possible regimens for the use of endocrine therapy are being made. Thus, in the SOLE study, after a mean follow-up of 84 months, 7-year disease-free survival was 81.4% in the intermittent therapy group and 81.5% in the continuous therapy group. Prolonged adjuvant endocrine therapy with intermittent letrozole did not improve relapse-free survival compared with continuous use, despite restoration of circulating estrogen levels.
Full Text
About the authors
Maryam A. Dzhelyalova
N. Petrov National Medical Research Center of Oncology
Email: gub.mariam@gmail.com
Saint Petersburg, Russia
V. F Semiglazov
N. Petrov National Medical Research Center of OncologySaint Petersburg, Russia
References
- Семиглазов В.Ф. Криворотько П.В., Семиглазова Т.Ю. и др. Практические рекомендации по лечению рака молочной железы. М., 2017. 168 с
- Семиглазов В.В., Криворотько П.В., Семиглазов В.Ф. и др. Международные рекомендации по лечению раннего рака молочной железы. М., 2020. С. 220-32
- Siamon D.J., Neven P., Chia S., et al. Ribociciib pius fuivestrant for postmenopausai women with hormone receptor-positive, human epidermai growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 triai: updated overall survivai. Ann Oncoi. 2021;32(8):1015-24. Doi: 10.1016/j. annonc.2021.05.353.
- Hamiiton E., Infante J.R. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016;45:129-38. Doi: 10.1016/j. ctrv.2016.03.002.
- Fry D.W., Harvey P.J., Keiier P.R., et ai. Specific inhibition of cyciindependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Moi Cancer Ther. 2004;3(11):1427-38.
- Finn R.S., Dering J., Conkiin D., et ai. PD 0332991, a seiective cyciin D kinase 4/6 inhibitor, preferentiaiiy inhibits proiiferation of iuminai estrogen receptor-positive human breast cancer ceii iines in vitro. Breast Cancer Res. 2009;11(5):R77.
- Siamon D.J., Neven P, Chia S., et ai. Phase III randomized study of ribociciib and fuivestrant in hormone receptor-positive, human epidermai growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Ciin Oncoi. 2018;36(24):2465-72. Doi: 10.1200/ JCO.2018.78.9909.
- Hortobagyi G.N., Stemmer S.M., Burris H.A., et ai. Ribociciib as first-iine therapy for HR-positive, advanced breast cancer. N Engi J Med. 2016;375(18):1738-48. Doi: 10.1056/ NEJMoa1609709.
- Siamon D.J., Neven P, Chia S., et ai. Overaii survivai with ribociciib pius fuivestrant in advanced breast cancer. N Engi J Med. 2020;382(6):514-24.
- Im S.A., Lu Y.S., Bardia A., et ai. Overaii survivai with ribociciib pius endocrine therapy in breast cancer. N Engi J Med. 2019;381(4):307-16. doi: 10.1056/NEJMoa1903765.
- Siedge G.W., Toi M., Neven P, et ai. The effect of abemaciciib pius fuivestrant on overaii survivai in hormone receptor-positive, ERBB2- negative breast cancer that progressed on endocrine therapy MONARCH 2: a randomized ciinicai triai. JAMA. Oncoi. 2019;6(1):116-24. Doi: 10.1001/ jamaoncoi.2019.4782.
- Goetz M.P., Toi M., Campone M., et ai. MONARCH 3: abemaciciib as initiai therapy for advanced breast cancer. J Ciin Oncoi. 2017;35(32):3638-
- doi: 10.1200/JCO.2017.75.6155.
- Turner N.C., Siamon D.J., Ro J., et ai. Overaii survivai with paibociciib and fuivestrant in advanced breast cancer. N Engi J Med. 2018;379(20):1926-36. doi: 10.1056/NEJMoa1810527.
- Tripathy D., Im S.-A., Coiieoni M., et ai. Updated overaii survivai (OS) resuits from the phase III MONALEESA-7 triai of pre-or perimenopausai patients with HR+/HER2-advanced breast cancer (ABC) treated with endocrine therapy (ET)+ribociciib. SABCS. 2020. Poster PD2-04.
- Jerusaiem G., Farah S., Courtois A., et ai. Continuous versus intermittent extended adjuvant ietrozoie for breast cancer: finai resuits of randomized phase III SOLE (Study of Letrozoie Extension) and SOLE Estrogen Substudy. Ann Oncoi. 2021;32(10):1256-66. Doi: 10.1016/j. annonc.2021.07.017.
Supplementary files
